• Attribution:

  • Goede V (German CLL Study Group Colonge, Germany)

  • VJHHemOnc-Video Journal of Hematological Oncology Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL. https://www.youtube.com/watch?v=IZnO4D8i4Ng ⁴

  • VJHHemOnc Youtube Channel:  https://www.youtube.com/channel/UCsQXL4_zTA-FoG9RA1tEGiw

Previous Video

Next Video